Alfavision Overseas (India) Limited (ALFAVIO.BO)
INR 12.69
(1.44%)
INR 12.69
(1.44%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 1.36 Billion INR | -15.46% |
| 2022 | 1.61 Billion INR | -40.44% |
| 2021 | 2.71 Billion INR | 166.16% |
| 2020 | 1.01 Billion INR | 14.34% |
| 2019 | 891.36 Million INR | 72.92% |
| 2018 | 515.48 Million INR | 51.2% |
| 2017 | 340.94 Million INR | -4.5% |
| 2016 | 357.01 Million INR | 181.77% |
| 2015 | 126.7 Million INR | -18.35% |
| 2014 | 155.18 Million INR | 83.53% |
| 2013 | 84.55 Million INR | 112.42% |
| 2012 | 39.8 Million INR | 4.21% |
| 2011 | 38.19 Million INR | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 Q3 | - INR | -100.0% |
| 2023 Q2 | 1.27 Billion INR | 0.0% |
| 2023 Q1 | - INR | -100.0% |
| 2023 Q4 | 1.36 Billion INR | 0.0% |
| 2023 FY | 1.36 Billion INR | -15.46% |
| 2022 Q1 | - INR | -100.0% |
| 2022 FY | 1.61 Billion INR | -40.44% |
| 2022 Q3 | - INR | -100.0% |
| 2022 Q4 | 1.61 Billion INR | 0.0% |
| 2022 Q2 | 2.19 Billion INR | 0.0% |
| 2021 Q2 | 1.18 Billion INR | 0.0% |
| 2021 FY | 2.71 Billion INR | 166.16% |
| 2021 Q4 | 2.71 Billion INR | 0.0% |
| 2021 Q3 | - INR | -100.0% |
| 2021 Q1 | - INR | -100.0% |
| 2020 Q2 | 971.96 Million INR | 0.0% |
| 2020 FY | 1.01 Billion INR | 14.34% |
| 2020 Q4 | 1.02 Billion INR | 0.0% |
| 2019 Q2 | 605.52 Million INR | 0.0% |
| 2019 FY | 891.36 Million INR | 72.92% |
| 2019 Q4 | 891.36 Million INR | 0.0% |
| 2018 Q4 | 515.48 Million INR | 0.0% |
| 2018 Q2 | 374.9 Million INR | 0.0% |
| 2018 FY | 515.48 Million INR | 51.2% |
| 2017 Q3 | 642 Million INR | 170.2% |
| 2017 Q2 | 237.6 Million INR | 17.38% |
| 2017 Q1 | 202.42 Million INR | -43.14% |
| 2017 FY | 340.94 Million INR | -4.5% |
| 2017 Q4 | 354.18 Million INR | -44.83% |
| 2016 FY | 357.01 Million INR | 181.77% |
| 2016 Q4 | 356.01 Million INR | 219.34% |
| 2016 Q3 | 111.48 Million INR | 24.32% |
| 2016 Q2 | 89.67 Million INR | -29.94% |
| 2016 Q1 | 127.99 Million INR | 1.02% |
| 2015 Q2 | 365.5 Million INR | 184.87% |
| 2015 FY | 126.7 Million INR | -18.35% |
| 2015 Q1 | 128.3 Million INR | -17.32% |
| 2015 Q4 | 126.7 Million INR | -62.65% |
| 2015 Q3 | 339.19 Million INR | -7.2% |
| 2014 Q1 | 83.39 Million INR | -1.37% |
| 2014 FY | 155.18 Million INR | 83.53% |
| 2014 Q4 | 155.18 Million INR | -9.16% |
| 2014 Q3 | 170.82 Million INR | 36.98% |
| 2014 Q2 | 124.71 Million INR | 49.54% |
| 2013 Q3 | 154.76 Million INR | 105.96% |
| 2013 Q4 | 84.55 Million INR | -45.36% |
| 2013 Q1 | 63.14 Million INR | 58.61% |
| 2013 FY | 84.55 Million INR | 112.42% |
| 2013 Q2 | 75.14 Million INR | 19.01% |
| 2012 FY | 39.8 Million INR | 4.21% |
| 2012 Q4 | 39.8 Million INR | -49.7% |
| 2012 Q3 | 79.14 Million INR | 0.0% |
| 2011 FY | 38.19 Million INR | 0.0% |
| 2011 Q4 | 27.7 Million INR | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Biocon Limited | 307.95 Billion INR | 99.556% |
| Blue Jet Healthcare Limited | 2.13 Billion INR | 36.06% |
| Concord Biotech Limited | 1.74 Billion INR | 21.528% |
| Dishman Carbogen Amcis Limited | 39.53 Billion INR | 96.545% |
| FERMENTA BIOTECH LIMITED | 2.62 Billion INR | 47.999% |
| GENOMIC VALLEY BIOTECH LIMITED | 7.91 Million INR | -17154.722% |
| Lyka Labs Limited | 884.58 Million INR | -54.412% |
| Panacea Biotec Limited | 4.02 Billion INR | 66.024% |
| SAMSRITA LABS LIMITED | 32.93 Million INR | -4047.275% |
| Servoteach Industries Limited | 5275.00 INR | -25893833.649% |
| SMS Lifesciences India Limited | 1.96 Billion INR | 30.623% |
| Supriya Lifescience Limited | 1.05 Billion INR | -29.017% |
| Syngene International Limited | 18.93 Billion INR | 92.788% |
| TAKE Solutions Limited | 969.78 Million INR | -40.847% |
| Titan Biotech Limited | 231.28 Million INR | -490.567% |
| Transgene Biotek Limited | 393.11 Million INR | -247.46% |
| Vanta Bioscience Limited | 724.23 Million INR | -88.6% |